Madison, Wisconsin headquartered Exact Sciences Corp.'s stock finished Wednesday's session 1.57% lower at $19.44 with a total volume of 1.60 million shares traded. Over the past three months and the previous one year, shares of Exact Sciences, which focuses on developing products for the early detection and prevention of various cancers, have rallied 60.07% and 150.52%, respectively. The Company's shares are trading above its 200-day moving average by 75.14%. Exact Sciences' stock has a Relative Strength Index (RSI) of 50.02. Free research report on EXAS is available at:
Great Basin Scientific
Salt Lake City, Utah headquartered Great Basin Scientific Inc.'s stock surged 25.00%, to close the day at $0.04. The stock recorded a trading volume of 12.82 million shares, which was above its three months average volume of 2.92 million shares. Shares of Great Basin Scientific, which develops and commercializes molecular diagnostic systems that are designed to test hospital-acquired infections, are trading 99.56% and 99.99% below its 50-day and 200-day moving averages, respectively. Additionally, the stock has an RSI of 9.08. The complimentary research report on GBSN can be downloaded at:
On Wednesday, shares in Santa Clara, California headquartered Agilent Technologies Inc. ended the session 1.28% higher at $46.02 with a total volume of 1.77 million shares traded. Agilent Technologies' shares have advanced 0.93% in the previous one month and 28.07% in the past one year. Shares of the Company, which provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide, are trading at a PE ratio of 31.59. The stock is trading 7.70% above its 200-day moving average. Moreover, the Company's shares have an RSI of 47.77. Visit us today and access our complete research report on A at:
On Wednesday, shares in Fort Myers, Florida headquartered Neogenomics Inc. recorded a trading volume of 244,894 shares. The stock ended the day 0.90% lower at $7.67. Neogenomics' stock has gained 35.04% in the past one year. The Company is trading below its 50-day and 200-day moving averages by 4.72% and 0.28%, respectively. Furthermore, shares of Neogenomics, which through its subsidiaries, operates a network of cancer-focused genetic testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the US, have an RSI of 42.69.
On October 4th, 2016, research firm First Analysis Sec initiated an 'Overweight' rating on the Company's stock, issuing a target price of $11 per share. Get free access to your research report on NEO at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA